HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings

Zymeworks Inc. (NASDAQ:ZYME) – HC Wainwright boosted their Q3 2026 EPS estimates for shares of Zymeworks in a report released on Wednesday, August 26th. HC Wainwright analyst R. Burns now expects that the company will post earnings of $2.14 per share for the quarter, up from their prior forecast of $2.13. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.25 per share.

Several other analysts also recently weighed in on the company. Stifel Nicolaus set a $46.00 target price on Zymeworks in a research note on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a report on Friday, July 17th. Wells Fargo & Company lifted their price objective on shares of Zymeworks from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of Zymeworks in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft set a $32.00 target price on shares of Zymeworks in a research report on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zymeworks has an average rating of “Moderate Buy” and a consensus price target of $40.00.

Zymeworks Trading Up 6.7%

Shares of NASDAQ ZYME opened at $29.31 on Thursday. Zymeworks has a 12-month low of $13.60 and a 12-month high of $30.62. The company has a market cap of $2.08 billion, a PE ratio of -14.51 and a beta of 1.15. The stock has a 50 day simple moving average of $24.73 and a 200-day simple moving average of $24.77.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). The firm had revenue of $3.23 million during the quarter, compared to analyst estimates of $4.54 million. Zymeworks had a negative net margin of 405.31% and a negative return on equity of 72.30%. Zymeworks’s revenue for the quarter was down 90.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.03 EPS.

Institutional Investors Weigh In On Zymeworks

Several hedge funds and other institutional investors have recently bought and sold shares of ZYME. BlackRock Inc. bought a new stake in Zymeworks during the second quarter worth approximately $111,122,000. Siren L.L.C. bought a new position in shares of Zymeworks in the fourth quarter valued at $44,238,000. Rubric Capital Management LP lifted its position in shares of Zymeworks by 21.7% during the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $175,280,000 after acquiring an additional 1,250,000 shares during the last quarter. Perceptive Advisors LLC lifted its position in shares of Zymeworks by 56.0% during the 4th quarter. Perceptive Advisors LLC now owns 3,261,850 shares of the company’s stock valued at $85,885,000 after acquiring an additional 1,171,187 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Zymeworks by 851.6% during the 3rd quarter. Millennium Management LLC now owns 1,104,813 shares of the company’s stock worth $18,870,000 after acquiring an additional 988,711 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

Zymeworks declared that its Board of Directors has initiated a share buyback program on Thursday, May 14th that authorizes the company to repurchase $125.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 7% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Key Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Jazz’s FDA approval covers Ziihera-based regimens for first-line treatment of adults with unresectable or metastatic HER2-positive GEA, including use regardless of PD-L1 status in certain patients. Phase 3 data showed median overall survival of more than two years, strengthening the commercial outlook for the therapy. Zymeworks FDA approval and milestone announcement
• Positive Sentiment: The approval triggers a $250 million milestone payment from Jazz, bringing total upfront and milestone payments from the partner to $650 million. Zymeworks also remains eligible for up to $1.3 billion in additional Jazz milestones and tiered royalties of 10% to 20% on net sales, plus potential payments and royalties from its BeOne collaboration. Zymeworks gains milestone from Jazz FDA approval
• Positive Sentiment: Analysts raised their valuation estimates: HC Wainwright increased its price target to $55 from $51 and maintained a Buy rating; Citigroup raised its target to $38 from $37 and also maintained Buy. Citizens JMP reaffirmed Market Outperform with a $32 target. Analyst target increases
• Neutral Sentiment: The FDA approval is supported by Phase 3 results, but the confirmatory trial remains ongoing and additional analyses are planned. Continued approval for an earlier biliary tract cancer indication may also depend on confirmatory evidence.
• Negative Sentiment: Zymeworks remains dependent on Jazz and BeOne for development, regulatory execution and commercialization. Delays, weaker-than-expected sales, unsuccessful confirmatory trials or safety concerns could reduce future milestone and royalty income.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.